Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
Description
CONCLUSIONS AND RELEVANCE: In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings
